Quote:
|
When given in two full-strength doses, AstraZeneca’s vaccine showed 62 percent efficacy in clinical trials — considerably lower than the roughly 95 percent efficacy achieved by Pfizer and Moderna’s shots. For reasons that scientists do not yet understand, AstraZeneca’s vaccine showed 90 percent efficacy in a smaller group of volunteers who were given a half-strength initial dose.
|
https://www.nytimes.com/2020/12/30/world/europe/uk-covid-19-vaccine-oxford-astrazeneca.html
Easier to distribute w/o the super refrigeration requirements of Modena, US has apparently secured 300 million doses, but it's not yet approved.
Is 60-70% enough? 90% press release boosted the stock, but does little for my faith.
By securing more doses, is this what the 'Average Joe' gets while those in the loop get the good stuff?
https://www.foxnews.com/health/uk-approves-astrazeneca-oxford-university-covid-19-vaccine
Quote:
The vaccine was developed using more traditional methods as opposed to the mRNA technology platform that was used for both Moderna and Pfizer’s vaccines.
The Oxford-AstraZeneca option involves an inactivated common cold virus isolated from chimpanzees, altered with genes to express the spike protein of the SARS-CoV-2 virus.
|
I think I want the high-tech mRNA option.